Deep learning for prioritizing small molecules candidates for drug repositioning

点击翻译按钮获取中文摘要

Sightline Innovation is a company that provides artificial intelligence products and solutions for businesses around the world. One of the areas that the company is interested in uses its deep learning cloud services to develop custom applications of the existing drugs for new therapeutic purposes, also called drug repositioning, in cancer that can be easily adjusted to specific client's requirements. Currently, the company has access to a large amount of pharmacogenomic data and drug compound structures for various drug repositioning tasks from different clients. The company is interested in exploiting these data to develop deep learning based solutions for drug repositioning systems that can be quickly adapted to specific clients. In the proposed research, we will accomplish this goal by unifying the structures of small molecules and pharmacogenomic data with neural networks of various architectures . Dr. Hu is a leader in developing deep learning models for drug repositioning. The Hu lab has more than 10 graduate student trainees and research associates with background in computer science, statistics, medical genetics, medicine and others. Sightline Innovation provides cutting-edge artificial intelligence solutions to multiple industries, including pharmaceutical industry. The company is constantly exploring new ways to enhance their products with advanced intelligence and analytic capabilities. The technology solutions developed in this project will provide the partner company with some unique product and market advantage, which may improve the lives of Canadians..